Prosonix teams with ICL to assess MCPs for COPD and asthma

By Gareth Macdonald

- Last updated on GMT

Related tags Asthma

Prosonix ICL MCP drug delivery
Prosonix aims to develop new treatments for respiratory diseases though an R&D accord formed with Imperial College London (ICL).

The aim is to assess how Prosonix’s multi-component particles (MCPs) - which are precise, excipient-free combinations of drugs designed for delivery via inhalation - ​can be turned into treatments for chronic obstructive pulmonary disease (COPD) and asthma.

Prosonix hopes to advance one or more of its portfolio of MCPs – which include combinations of inhaled corticosteroids (ICS) and long-acting beta-agonist (LABA) as well as LABAs with long-acting muscarinic antagonists (LAMA) - into preclinical studies by 2013.

The UK drug developer – which has a background in particle engineering – ​will assess the particles according to various performance criteria, one of which – co-localisation – could lead to the development of more effective treatments according to Omar Usmani from ICL’s National Heart and Lung Institute (NHLI)

"Co-localisation of active components in respiratory drug combinations in the lung may offer the potential for an enhanced clinical effect and therapeutic efficacy that is currently not fully achieved with current combinations.

“With better treatment of respiratory diseases requiring improved combinations for these reasons, we are extremely interested in Prosonix' particle engineering approach and multi-component particles to determine whether they can demonstrate clinical synergy and thus provide a novel and effective means of delivering respiratory combinations."

Prosonix CEO David Hipkiss was similarly upbeat about the project, setting it in the context of the firms wider growth plans.

“We believe that our particle engineering technology is potentially transformational in enabling the development of novel inhaled combination therapies that deliver significant clinical benefits.

“Following the recent second close of our £17.1M financing, we believe we are very well placed now to drive the development of our unique MCPs into the clinic.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us


View more